Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis
Abstract Background Lymphedema, the accumulation of interstitial fluid caused by poor lymphatic drainage, is a progressive and permanent disease with no curative treatment. Several studies have evaluated cell-based therapies in secondary lymphedema, but no meta-analysis has been performed to assess...
Guardado en:
Autores principales: | , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ce46e23cc8824a7db5073ff465a6cd69 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:ce46e23cc8824a7db5073ff465a6cd69 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:ce46e23cc8824a7db5073ff465a6cd692021-11-21T12:04:44ZCell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis10.1186/s13287-021-02632-y1757-6512https://doaj.org/article/ce46e23cc8824a7db5073ff465a6cd692021-11-01T00:00:00Zhttps://doi.org/10.1186/s13287-021-02632-yhttps://doaj.org/toc/1757-6512Abstract Background Lymphedema, the accumulation of interstitial fluid caused by poor lymphatic drainage, is a progressive and permanent disease with no curative treatment. Several studies have evaluated cell-based therapies in secondary lymphedema, but no meta-analysis has been performed to assess their efficacy. Methods We conducted a systematic review and meta-analysis of all available preclinical and clinical studies, with assessment of their quality and risk of bias. Results A total of 20 articles using diverse cell types were selected for analysis, including six clinical trials and 14 pre-clinical studies in three species. The meta-analysis showed a positive effect of cell-based therapies on relevant disease outcomes (quantification of edema, density of lymphatic capillaries, evaluation of the lymphatic flow, and tissue fibrosis). No significant publication bias was observed. Conclusion Cell-based therapies have the potential to improve secondary lymphedema. The underlying mechanisms remain unclear. Due to relevant heterogeneity between studies, further randomized controlled and blinded studies are required to substantiate the use of these novel therapies in clinical practice.Hector LafuenteIbon JaunarenaEukene AnsuateguiArantza LekuonaAnder IzetaBMCarticleStem cellsLymphatic vasculatureLymphedemaRegenerationRegenerative medicineSystematic reviewMedicine (General)R5-920BiochemistryQD415-436ENStem Cell Research & Therapy, Vol 12, Iss 1, Pp 1-17 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
Stem cells Lymphatic vasculature Lymphedema Regeneration Regenerative medicine Systematic review Medicine (General) R5-920 Biochemistry QD415-436 |
spellingShingle |
Stem cells Lymphatic vasculature Lymphedema Regeneration Regenerative medicine Systematic review Medicine (General) R5-920 Biochemistry QD415-436 Hector Lafuente Ibon Jaunarena Eukene Ansuategui Arantza Lekuona Ander Izeta Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
description |
Abstract Background Lymphedema, the accumulation of interstitial fluid caused by poor lymphatic drainage, is a progressive and permanent disease with no curative treatment. Several studies have evaluated cell-based therapies in secondary lymphedema, but no meta-analysis has been performed to assess their efficacy. Methods We conducted a systematic review and meta-analysis of all available preclinical and clinical studies, with assessment of their quality and risk of bias. Results A total of 20 articles using diverse cell types were selected for analysis, including six clinical trials and 14 pre-clinical studies in three species. The meta-analysis showed a positive effect of cell-based therapies on relevant disease outcomes (quantification of edema, density of lymphatic capillaries, evaluation of the lymphatic flow, and tissue fibrosis). No significant publication bias was observed. Conclusion Cell-based therapies have the potential to improve secondary lymphedema. The underlying mechanisms remain unclear. Due to relevant heterogeneity between studies, further randomized controlled and blinded studies are required to substantiate the use of these novel therapies in clinical practice. |
format |
article |
author |
Hector Lafuente Ibon Jaunarena Eukene Ansuategui Arantza Lekuona Ander Izeta |
author_facet |
Hector Lafuente Ibon Jaunarena Eukene Ansuategui Arantza Lekuona Ander Izeta |
author_sort |
Hector Lafuente |
title |
Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
title_short |
Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
title_full |
Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
title_fullStr |
Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
title_full_unstemmed |
Cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
title_sort |
cell therapy as a treatment of secondary lymphedema: a systematic review and meta-analysis |
publisher |
BMC |
publishDate |
2021 |
url |
https://doaj.org/article/ce46e23cc8824a7db5073ff465a6cd69 |
work_keys_str_mv |
AT hectorlafuente celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis AT ibonjaunarena celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis AT eukeneansuategui celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis AT arantzalekuona celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis AT anderizeta celltherapyasatreatmentofsecondarylymphedemaasystematicreviewandmetaanalysis |
_version_ |
1718419271497809920 |